Aclaris Therapeutics, Inc. generated $7.8M in revenue in fiscal year 2025. This represents a decrease of 58.2% from the prior fiscal year. Over the trailing 12 months, Q3 FY2025 through Q2 FY2026, the same line adds up to $8.2M in revenue. The table below carries 13 fiscal years, from 2013 to 2025, and the quarters Aclaris Therapeutics, Inc. has filed alongside them.
Annual figures, oldest first. Point at a bar to read its period.
ACRS Revenue by Fiscal Year
Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings.
ACRS Revenue by Quarter
Figures are as reported in USD. Each change compares the quarter with the same quarter a year earlier.
What revenue means
Revenue is everything the company billed its customers over the period, counted before any cost of running the business comes out of it.
More Aclaris Therapeutics, Inc. financials
Frequently Asked Questions
What was Aclaris Therapeutics, Inc.'s revenue in fiscal year 2025?
Aclaris Therapeutics, Inc. generated $7.8M in revenue in fiscal year 2025.
How fast is Aclaris Therapeutics, Inc.'s revenue growing?
Aclaris Therapeutics, Inc. (ACRS) revenue fell by 58.2% year over year, from $18.7M to $7.8M in fiscal year 2025.
What is Aclaris Therapeutics, Inc.'s revenue over the last twelve months?
Aclaris Therapeutics, Inc. (ACRS) reported $8.2M in revenue over the trailing 12 months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings.
What was Aclaris Therapeutics, Inc.'s revenue in the most recent quarter?
Aclaris Therapeutics, Inc. (ACRS) reported $1.6M in revenue in Q2 2026. This represents a decrease of 8.3% from the same quarter a year earlier.
What does revenue mean on a financial statement?
Revenue is everything the company billed its customers over the period, counted before any cost of running the business comes out of it. This page lists what Aclaris Therapeutics, Inc. (ACRS) reported on that line in every period on record.